BliNK Biomedical Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $1.84M
Latest Deal Amount
  • Investors
  • 4

BliNK Biomedical General Information

Description

Developer of a B cell technology designed to enable the selection and isolation of specific antibody-producing cells. The company's technology constitutes an efficient and deep mining process, enabling researchers to identify unique therapeutic antibodies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 17 Boulevard Cieussa
  • 13007 Marseille
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BliNK Biomedical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 12-Jul-2016 $1.84M 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 11-Dec-2014 00.000 00.000 Completed Generating Revenue
To view BliNK Biomedical’s complete valuation and funding history, request access »

BliNK Biomedical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a B cell technology designed to enable the selection and isolation of specific antibody-producing cells. Th
Biotechnology
Marseille, France
11 As of 2016
00.000
00000000000 00.000

00000000

smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000000000000
Vancouver, Canada
000 As of 0000
00000
00000000 00000

00000000

agna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000000000000
Gaithersburg, MD
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BliNK Biomedical Competitors (62)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AbCellera Venture Capital-Backed Vancouver, Canada 000 00000 00000000 00000
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
000000000 Formerly VC-backed Milpitas, CA 000 000000&0
0000000 Venture Capital-Backed San Diego, CA 00 00000 00000000 00000
0000 0000000000 Formerly VC-backed Beijing, China 000 00000 00000000 00000
You’re viewing 5 of 62 competitors. Get the full list »

BliNK Biomedical Executive Team (2)

Name Title Board Seat Contact Info
Jack Elands Ph.D Chief Executive Officer, Chairman & Manager
To view BliNK Biomedical’s complete executive team members history, request access »

BliNK Biomedical Board Members (8)

Name Representing Role Since
Franck Grimaud Valneva Board Member 000 0000
Jack Elands Ph.D BliNK Biomedical Chief Executive Officer, Chairman & Manager 000 0000
Michael Owen Ph.D Self Board Member 000 0000
Thierry Laugel Ph.D Kurma Partners Board Member 000 0000
You’re viewing 4 of 8 board members. Get the full list »

BliNK Biomedical Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BliNK Biomedical Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cancer Research UK Venture Capital Minority 000 0000 000000 0
Idinvest Partners PE/Buyout Minority 000 0000 000000 0
Kurma Partners Venture Capital Minority 000 0000 000000 0
Valneva Corporation Minority 000 0000 000000 0
To view BliNK Biomedical’s complete investors history, request access »